Literature DB >> 27736752

Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Gabriel Cabot1, Carla López-Causapé1, Alain A Ocampo-Sosa2, Lea M Sommer3, María Ángeles Domínguez4, Laura Zamorano1, Carlos Juan1, Fe Tubau4, Cristina Rodríguez2, Bartolomé Moyà1, Carmen Peña5, Luis Martínez-Martínez2,6, Patrick Plesiat7, Antonio Oliver8.   

Abstract

Whole-genome sequencing (WGS) was used for the characterization of the frequently extensively drug resistant (XDR) Pseudomonas aeruginosa sequence type 175 (ST175) high-risk clone. A total of 18 ST175 isolates recovered from 8 different Spanish hospitals were analyzed; 4 isolates from 4 different French hospitals were included for comparison. The typical resistance profile of ST175 included penicillins, cephalosporins, monobactams, carbapenems, aminoglycosides, and fluoroquinolones. In the phylogenetic analysis, the four French isolates clustered together with two isolates from one of the Spanish regions. Sequence variation was analyzed for 146 chromosomal genes related to antimicrobial resistance, and horizontally acquired genes were explored using online databases. The resistome of ST175 was determined mainly by mutational events; resistance traits common to all or nearly all of the strains included specific ampR mutations leading to ampC overexpression, specific mutations in oprD conferring carbapenem resistance, or a mexZ mutation leading to MexXY overexpression. All isolates additionally harbored an aadB gene conferring gentamicin and tobramycin resistance. Several other resistance traits were specific to certain geographic areas, such as a streptomycin resistance gene, aadA13, detected in all four isolates from France and in the two isolates from the Cantabria region and a glpT mutation conferring fosfomycin resistance, detected in all but these six isolates. Finally, several unique resistance mutations were detected in single isolates; particularly interesting were those in genes encoding penicillin-binding proteins (PBP1A, PBP3, and PBP4). Thus, these results provide information valuable for understanding the genetic basis of resistance and the dynamics of the dissemination and evolution of high-risk clones.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27736752      PMCID: PMC5119024          DOI: 10.1128/AAC.01720-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

Review 1.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

2.  Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure.

Authors:  Alaa Ropy; Gabriel Cabot; Irina Sánchez-Diener; Cristian Aguilera; Bartolome Moya; Juan A Ayala; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

3.  Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Patrice Nordmann; Farid El Garch; Ludovic Cabanne; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 4.  Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.

Authors:  Shaan L Gellatly; Robert E W Hancock
Journal:  Pathog Dis       Date:  2013-03-15       Impact factor: 3.166

Review 5.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

Authors:  N Mesaros; P Nordmann; P Plésiat; M Roussel-Delvallez; J Van Eldere; Y Glupczynski; Y Van Laethem; F Jacobs; P Lebecque; A Malfroot; P M Tulkens; F Van Bambeke
Journal:  Clin Microbiol Infect       Date:  2007-01-31       Impact factor: 8.067

Review 6.  Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance.

Authors:  Neil Woodford; Jane F Turton; David M Livermore
Journal:  FEMS Microbiol Rev       Date:  2011-03-01       Impact factor: 16.408

Review 7.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 8.  Nosocomial infections in adult intensive-care units.

Authors:  Jean-Louis Vincent
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

10.  Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone.

Authors:  Esther Viedma; Carlos Juan; Joaquín R Otero; Antonio Oliver; Fernando Chaves
Journal:  Genome Announc       Date:  2013-04-11
View more
  35 in total

1.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

2.  Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.

Authors:  C A Colque; A G Albarracín Orio; S Feliziani; R L Marvig; A R Tobares; H K Johansen; S Molin; A M Smania
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.

Authors:  Pablo A Fraile-Ribot; Xavier Mulet; Gabriel Cabot; Ester Del Barrio-Tofiño; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting.

Authors:  Carla López-Causapé; Rosa Rubio; Gabriel Cabot; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308.

Authors:  Pablo A Fraile-Ribot; Cristóbal Del Rosario-Quintana; Carla López-Causapé; María A Gomis-Font; Mar Ojeda-Vargas; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 6.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

7.  Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.

Authors:  Ester Del Barrio-Tofiño; Carla López-Causapé; Gabriel Cabot; Alba Rivera; Natividad Benito; Concepción Segura; María Milagro Montero; Luisa Sorlí; Fe Tubau; Silvia Gómez-Zorrilla; Nuria Tormo; Raquel Durá-Navarro; Esther Viedma; Elena Resino-Foz; Marta Fernández-Martínez; Claudia González-Rico; Izaskun Alejo-Cancho; Jose Antonio Martínez; Cristina Labayru-Echverria; Carlos Dueñas; Ignacio Ayestarán; Laura Zamorano; Luis Martinez-Martinez; Juan Pablo Horcajada; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

8.  Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model.

Authors:  M Montero; Brian D VanScoy; Carla López-Causapé; Haley Conde; Jonathan Adams; Concepción Segura; Laura Zamorano; Antonio Oliver; Juan P Horcajada; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

9.  Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.

Authors:  Irina Sánchez-Diener; Laura Zamorano; Carla López-Causapé; Gabriel Cabot; Xavier Mulet; Carmen Peña; Rosa Del Campo; Rafael Cantón; Antonio Doménech-Sánchez; Luis Martínez-Martínez; Susana C Arcos; Alfonso Navas; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam.

Authors:  Fernando Sanz-García; Sara Hernando-Amado; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.